205 related articles for article (PubMed ID: 34638392)
1. Role of Resin Microsphere Y90 Dosimetry in Predicting Objective Tumor Response, Survival and Treatment Related Toxicity in Surgically Unresectable Colorectal Liver Metastasis: A Retrospective Single Institution Study.
Sankhla T; Cheng B; Nezami N; Xing M; Sethi I; Bercu Z; Brandon D; Majdalany B; Schuster DM; Kokabi N
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638392
[TBL] [Abstract][Full Text] [Related]
2. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study.
Kokabi N; Arndt-Webster L; Chen B; Brandon D; Sethi I; Davarpanahfakhr A; Galt J; Elsayed M; Bercu Z; Cristescu M; Kappadath SC; Schuster DM
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1743-1752. PubMed ID: 36650357
[TBL] [Abstract][Full Text] [Related]
3. Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization.
Cheng B; Villalobos A; Sethi I; Wagstaff W; Galt J; Brandon D; Schuster DM; Bercu Z; Majdalany B; Kokabi N
Cardiovasc Intervent Radiol; 2021 Aug; 44(8):1194-1203. PubMed ID: 33890170
[TBL] [Abstract][Full Text] [Related]
4. Impact of Genomic Mutation and Timing of Y90 Radioembolization in Colorectal Liver Metastases.
Dabrowiecki A; Sankhla T; Shinn K; Bercu ZL; Ermentrout M; Shaib W; Cardona K; Newsome J; Kokabi N
Cardiovasc Intervent Radiol; 2020 Jul; 43(7):1006-1014. PubMed ID: 32367230
[TBL] [Abstract][Full Text] [Related]
5. Resin-Based 90 Y Tumor Dose as a Predictor of Duration of Response and Survival in Patients With Surgically Unresectable Hepatocellular Carcinoma : A Prospective Single-Arm Study.
Kokabi N; Webster LA; Dabbous H; Shah A; Brandon D; Galt J; Xing M; Villalobos A; Davarpanahfakhr A; Kappadath SC; Schuster DM
Clin Nucl Med; 2024 May; ():. PubMed ID: 38861361
[TBL] [Abstract][Full Text] [Related]
6. Yttrium-90 dosimetry and implications on tumour response and survival after radioembolisation of chemo-refractory hepatic metastases from breast cancer.
Cheng B; Sethi I; Davisson N; Brandon D; Barron B; Galt J; Bercu Z; Schuster DM; Kokabi N
Nucl Med Commun; 2021 Apr; 42(4):402-409. PubMed ID: 33306630
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
[TBL] [Abstract][Full Text] [Related]
8. Determination of tumour dose response threshold and implication on survival in patients with HCC treated with Y90 radiation segmentectomy: a simple semi-quantitative analysis.
Cheng B; Sethi I; Villalobos A; Wagstaff W; Schuster DM; Bercu Z; Brandon D; Kokabi N
Nucl Med Commun; 2021 Aug; 42(8):892-898. PubMed ID: 33795611
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of unresectable hepatocellular carcinoma treated with yttrium-90 radioembolization: results from a large cohort over 13 years at a single center.
Shah RM; Sheikh S; Shah J; Vivian E; Mejia A; Shahin I; Mantry PS
J Gastrointest Oncol; 2021 Aug; 12(4):1718-1731. PubMed ID: 34532122
[TBL] [Abstract][Full Text] [Related]
10. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
[TBL] [Abstract][Full Text] [Related]
11. Correlation of Non-tumoral Liver Dose with Treatment-Related Adverse Events in Patients with Hepatocellular Carcinoma Treated with Glass-Based Yttrium-90 Radioembolization.
Webster LA; Villalobos A; Cheng B; Xing M; Majdalany BS; Bercu ZL; Cristescu MM; Brandon D; Schuster D; Baum Y; Loya MF; Kokabi N
Cardiovasc Intervent Radiol; 2023 Jan; 46(1):60-68. PubMed ID: 36450996
[TBL] [Abstract][Full Text] [Related]
12. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
[TBL] [Abstract][Full Text] [Related]
13. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
[TBL] [Abstract][Full Text] [Related]
14. For Hepatocellular Carcinoma Treated with Yttrium-90 Microspheres, Dose Volumetrics on Post-Treatment Bremsstrahlung SPECT/CT Predict Clinical Outcomes.
Taswell CS; Studenski M; Pennix T; Stover B; Georgiou M; Venkat S; Jones P; Zikria J; Thornton L; Yechieli R; Mohan P; Portelance L; Spieler B
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765603
[TBL] [Abstract][Full Text] [Related]
15. 3D voxel-based dosimetry to predict contralateral hypertrophy and an adequate future liver remnant after lobar radioembolization.
Grisanti F; Prieto E; Bastidas JF; Sancho L; Rodrigo P; Beorlegui C; Iñarrairaegui M; Bilbao JI; Sangro B; Rodríguez-Fraile M
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3048-3057. PubMed ID: 33674893
[TBL] [Abstract][Full Text] [Related]
16. A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and
Manceau V; Palard X; Rolland Y; Pracht M; Le Sourd S; Laffont S; Boudjema K; Lievre A; Mesbah H; Haumont LA; Lenoir L; Brun V; Uguen T; Edeline J; Garin E
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1731-1741. PubMed ID: 29560519
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization.
Levey AO; Elsayed M; Lawson DH; Ermentrout RM; Kudchadkar RR; Bercu ZL; Yushak ML; Newsome J; Kokabi N
Cardiovasc Intervent Radiol; 2020 Feb; 43(2):254-263. PubMed ID: 31686137
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of ADC measurements in predicting overall survival in patients undergoing
Alis D; Durmaz ESM; Gulsen F; Bas A; Kabasakal L; Sager S; Numan F
Clin Imaging; 2019; 57():124-130. PubMed ID: 31220677
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Hepatic Artery Infusion (HAI) Versus Selective Internal Radiation Therapy (Y90) for Pretreated Isolated Unresectable Colorectal Liver Metastases (IU-CRCLM).
Dhir M; Zenati MS; Jones HL; Bartlett DL; Choudry MHA; Pingpank JF; Holtzman MP; Bahary N; Hogg ME; Zeh HJ; Geller DA; Wallis Marsh J; Tsung A; Zureikat AH
Ann Surg Oncol; 2018 Feb; 25(2):550-557. PubMed ID: 29181682
[TBL] [Abstract][Full Text] [Related]
20. Quantitative comparison of pre-treatment predictive and post-treatment measured dosimetry for selective internal radiation therapy using cone-beam CT for tumor and liver perfusion territory definition.
Jafargholi Rangraz E; Tang X; Van Laeken C; Maleux G; Dekervel J; Van Cutsem E; Verslype C; Baete K; Nuyts J; Deroose CM
EJNMMI Res; 2020 Aug; 10(1):94. PubMed ID: 32797332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
